Compare AbCellera Biologics Inc (ABCL) vs Roblox Corp (RBLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Roblox Corp — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Roblox Corp trades at $54.46 (market cap $40.60B). The key difference: Roblox Corp is far larger — about 17.3× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals.
| ABCL | RBLX | |
|---|---|---|
Market Cap | $2.35B | $40.60B |
Sector | Health | Media |
52-Week High | $8.12 | $141.56 |
52-Week Low | $2.78 | $41.30 |
Enterprise Value | $1.99B | $39.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Roblox trades at $56.70, up 2.31% with strong technical momentum and bullish moving average signals. The company shows impressive revenue growth to $4.89 billion in 2025 and positive operating cash flow of $1.80 billion, though it remains unprofitable with a -20.69% net margin. Recent earnings beats and analyst consensus of $64.07 price target suggest upside potential, but multiple class action lawsuits filed in July 2026 create significant legal overhang.
While Roblox demonstrates strong user monetization and cash generation, profitability challenges and legal risks weigh on investor sentiment. The stock offers growth exposure but requires careful risk management given the negative earnings profile and ongoing litigation. Analyst optimism appears tempered by fundamental weaknesses and recent legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
